News

Immunic, Inc. Outlines Upcoming Conferences for November 2025

Immunic, Inc. Outlines Upcoming Conferences for November 2025

Immunic, Inc. Announces Conference Participation for November

NEW YORK — Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, has announced its participation in key industry and investor conferences this coming November.

Details of Upcoming Conferences

Immunic is set to join various industry forums including:

BIO-Europe Conference

From November 3-5, key members of the Immunic team, including CEO Daniel Vitt, Ph.D., Chief Scientific Officer Hella Kohlhof, Ph.D., and Vice President of Investor Relations and Communications Jessica Breu, will engage in partnering activities at the BIO-Europe Conference held in Vienna, Austria. Interested parties can utilize the official partnering system to schedule meetings.

Jefferies Global Healthcare Conference

Additionally, Dr. Vitt, alongside Jason Tardio, President and COO of Immunic, will host one-on-one meetings in London on November 19-20. This event is in conjunction with the Jefferies Global Healthcare Conference - London. Stakeholders should reach out to Jessica Breu to arrange discussions during this opportunity.

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) specializes in small molecule therapies aimed at treating chronic inflammatory and autoimmune conditions. Their lead candidate, vidofludimus calcium (IMU-838), is undergoing phase 3 trials targeting relapsing multiple sclerosis, showcasing promising therapeutic activity based on prior phase 2 results. This innovative therapy works on neuroprotection while also addressing inflammation.

Moreover, Immunic is developing IMU-856 to enhance intestinal barrier function, which may benefit various gastrointestinal disorders. Their commitment also includes developing IMU-381, currently in preclinical stages, designed to meet the needs of patients with gastrointestinal issues.

Further Information

For more information about Immunic's initiatives and upcoming presentations, please visit their official website. The firm continues to advance its projects and engage with the healthcare investor community to share its vision and developments.

Frequently Asked Questions

What is the focus of Immunic, Inc.?

Immunic, Inc. is focused on developing small molecule therapies for chronic inflammatory and autoimmune diseases.

What major conferences will Immunic participate in this November?

The company will be attending the BIO-Europe Conference from November 3-5 and the Jefferies Global Healthcare Conference on November 19-20.

Who are the key personnel attending these events?

Key personnel include CEO Daniel Vitt and President and COO Jason Tardio, along with Jessica Breu, the Vice President of Investor Relations.

What is vidofludimus calcium?

Vidofludimus calcium (IMU-838) is Immunic's lead therapeutic candidate, currently in phase 3 clinical trials for treating relapsing multiple sclerosis.

How can I schedule a meeting with Immunic's representatives?

Interested individuals should contact Jessica Breu or utilize the digital partnering platform for the conferences.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 37

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 52

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 46

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 63

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 40

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 35

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 28

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading

Top 5 Most Recently Viewed Articles

Aurelia Cellular Vitality Launch: Beauty Supplements Shake Up U.S. Market

Updated Category News Views 171

Aurelia Cellular Vitality just hit the U. S. market on February 17, 2026, and this ain't just another beauty brand strutting in with flashy ads and pretty bottles. They’re packing some serious science behind their hair, skin, and nail supplements formulated with their proprietary Eternacell™ complex designed to hit cellular-level vitality hard—think anti-aging but...

Continue Reading
Upcoming Financial Results Announcement for EWCZ

Updated Category News Views 117

Exciting Developments Ahead for European Wax Center, Inc. European Wax Center, Inc. (NASDAQ: EWCZ), recognized as a prominent franchisor specializing in out-of-home waxing services across the United States, is gearing up to unveil significant financial reports. Anticipation builds as the company prepares to disclose its fourth-quarter and fiscal year 2024 financial...

Continue Reading
Revolutionizing Nutritional Understanding Through Innovative Science

Updated Category News Views 138

A Comprehensive Look at Nutrient Intake Measurement A recent innovative framework designed to measure nutrient absorption offers a new perspective on how we understand the nutrients our bodies utilize. Traditional methods often focus solely on the total nutrient content, neglecting a crucial factor in nutrient intake: how much of those nutrients are actually absorbed by...

Continue Reading
Jennifer Cable Joins J2 Ventures Advisory Board to Drive Innovation

Updated Category News Views 168

Back in the day, Jennifer Cable took the reins as President of Thorlabs, positioning herself at the forefront of optical technology. Fast forward to her latest move—she joined J2 Ventures' advisory board, which sent ripples through the deep tech landscape. Traders were buzzing; they knew this wasn’t just another face in the crowd. With over $250 million under...

Continue Reading
Unlocking Monthly Income with Bank of America Dividends

Updated Category News Views 101

Understanding Bank of America Stock Dividends Bank of America Corporation (NASDAQ: BAC) is set to announce its earnings for the second quarter soon, generating buzz among investors regarding its dividend potential. Its current annual dividend yield stands at 2.20%, which translates to a quarterly dividend of 26 cents per share or $1.04 annually. Calculating Monthly Income...

Continue Reading